Prevalence of hepatitis B and hepatitis C virus infections in france in 2004: Social factors are important predictors after adjusting for known risk factors

Journal of Medical Virology

Volumn 82, Issue 4, 2010, Pages 546-555

  Meffre, Christine ^a   Strat, Yann Le ^a   Delarocque Astagneau, Elisabeth ^a,b   Dubois, Fréderic ^c   Antona, Denise ^a   Lemasson, Jean Marie ^d   Warszawski, Josiane ^e   Steinmetz, Josiane ^f   Coste, Dominique ^d   Meyer, Jean François ^g   Leiser, Sandrine ^h   Giordanella, Jean Pierre ^h   Gueguen, René ^f   Desenclos, Jean Claude ^a  

^a National Institute for Public Health Surveillance   (France)

^b INSTITUT PASTEUR   (France)

^c Centre d'Examen de Santé de la Sécurité Sociale Irsa   (France)

^d Centre d'Examen de Santé de la Sécurité Sociale   (France)

^e INSERM   (France)

^f Centre Technique d'Appui et de Formation des Centres d'Examens de Sante Cetaf   (France)

^g Centre d'Examen de Santé de la Sécurité Sociale   (France)

^h Caisse Nationale d'Assurance Maladie des Travailleurs Salaries   (France)

Author keywords

Chronic hepatitis B and C; Cross sectional study; Prevalence; Risk factors; Socio economic factors

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B ANTIGEN; VIRUS RNA;

ADULT; AGED; ARTICLE; BLOOD TRANSFUSION; COMPUTER PROGRAM; CONTROLLED STUDY; DATA COLLECTION METHOD; DEMOGRAPHY; DRUG USE; FEMALE; HEALTH SURVEY; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; RISK FACTOR; SCREENING; SOCIAL ASPECT; SOCIOECONOMICS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CROSS-SECTIONAL STUDIES; FEMALE; FRANCE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; MALE; MIDDLE AGED; PREVALENCE; RISK FACTORS; RNA, VIRAL; SOCIOECONOMIC FACTORS; URBAN POPULATION; YOUNG ADULT;

HEPATITIS C VIRUS;

EID: 77949378880     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21734     Document Type: Article

References (48)

1. Alter MJ. 2003. Epidemiology of hepatitis B in Europe and worldwide. J Hepatol 39:S64-S69.
2. Alter MJ. 2007. Epidemiology of hepatitis C virus infection. World J Gastroenterol 13:2436-2441.
3. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA, Margolis HS. 1999. The prevalence of hepatitis C virus infection in the United States, 1988 through1994. N Engl J Med 341:556-562.
4. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. 2006. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 144:705-714.
5. Asensio F, Bayas JM, Bertran MJ, Asenjo MA. 2000. Prevalence of hepatitis B infection in long-stay mentally handicapped adults. Eur J Epidemiol 16:725-729.
6. Boisguérin B. 2005. Les bénéficiaires de la CMU au 31 décembre 2004 - Etudes et Résultats. Paris: Drees, no. 433. Available at: http://www.sante.gouv.fr/drees/etude-resultat/er433/er433.pdf.
7. Briggs ME, Baker C, Hall R, Gaziano JM, Gagnon D, Bzowej N, Wright TL. 2001. Prevalence and risk factors for hepatitis C virus infection at an urban Veterans Administration medical center. Hepatology 34:1200-1205.
8. Dalgard O, Jeansson S, Skaug K, Raknerud N, Bell H. 2003. Hepatitis C in the general adult population of Oslo: Prevalence and clinical spectrum. Scand J Gastroenterol 38:864-870.
9. Defossez G, Verneau A, Ingrand I, Silvain C, Ingrand P, Beauchant M. 2008. Evaluation of the French national plan to promote screening and early management of viral hepatitis C, between 1997 and 2003: A comparative cross-sectional study in Poitou-Charentes region. Eur J Gastroenterol Hepatol 20:367-372.
10. Denis F, Tabaste JL, Ranger-Rogez S. 1994. Prevalence of HBs Ag in about 21,500 pregnant women. Survey at twelve French University Hospitals. The Multicentric Study Group. Pathol Biol (Paris) 42:533-538.
11. Desenclos JC, Dubois F, Couturier E, Pillonel J, Roudot-Thoraval F, Guignard E, Brunet J-B, Drücker J. 1996. Estimation du nombre de sujets infectés par le VHC en France, 1994-1995. Bulletin Epidémiologique Hebdomadaire 5:22-23.
12. Deuffic-Burban S, Wong JB, Valleron AJ, Costagliola D, Delfraissy JF, Poynard T. 2004. Comparing the public health burden of chronic hepatitis C and HIV infection in France. J Hepatol 40:319-326.
13. Dubois F, Desenclos JC, Mariotte N, Goudeau A. 1997. Hepatitis C in a French population-based survey, 1994: Seroprevalence, frequency of viremia, genotype distribution, and risk factors. The Collaborative Study Group. Hepatology 25:1490-1496.
14. Emmanuelli J, Desenclos JC. 2005. Harm reduction interventions, behaviours and associated health outcomes in France, 1996-2003. Addiction 100:1690-1700.
15. Goudeau A, Dubois F. 1995. Incidence and prevalence of hepatitis B in France. Vaccine 13:S22-S25.
16. Greenland S. 1977. Response and follow-up bias in cohort studies. Am J Epidemiol 106:184-187.
17. Hagan H, Thiede H, Weiss NS, Hopkins SG, Duchin JS, Alexander ER. 2001. Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health 91:42-46.
18. Haley RW, Fischer RP. 2001. Commercial tattooing as a potentially important source of hepatitis C infection. Clinical epidemiology of 626 consecutive patients unaware of their hepatitis C serologic status. Medicine (Baltimore) 80:134-151.
19. Hosmer DW, Lemeshow S, editors. 2000. Applied logistic regression. 2nd edition. New York: John Wiley & Sons, Inc.
20. Jauffret-Roustide M, Le Strat Y, Couturier E, Thierry D, Rondy M, Quaglia M, Razafindratsima N, Emmanuelli J, Guibert G, Barin F, Desenclos JC. 2009. A national cross-sectional study among drug-users in France: Epidemiology of HCV and highlight on practical and statistical aspects of the design. BMC Infect Dis 9:113.
21. Lok AS, McMahon BJ. 2007. Chronic hepatitis B. Hepatology 45:507-539.
22. Lucidarme D, Bruandet A, Ilef D, Harbonnier J, Jacob C, Decoster A, Delamare C, Cyran C, Van Hoenacker AF, Fremaux D, Josse P, Emmanuelli J, Le Strat Y, Desenclos JC, Filoche B. 2004. Incidence and risk factors of HCV and HIV infections in a cohort of intravenous drug users in the North and East of France. Epidemiol Infect 132:699-708.
23. Marcellin P, Pequignot F, Delarocque-Astagneau E, Zarski JP, Ganne N, Hillon P, Antona D, Bovet M, Mechain M, Asselah T, Desenclos JC, Jougla E. 2008. Mortality related to chronic hepatitis B and chronic hepatitis C in France: Evidence for the role of HIV coinfection and alcohol consumption. J Hepatol 48:200-207.
24. Mast EE, Margolis HS, Fiore AE, Brink EW, Goldstein ST, Wang SA, Moyer LA, Bell BP, Alter MJ. 2005. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Part 1: Immunization of infants, children, and adolescents. MMWR Recomm Rep 54:1-31.
25. McQuillan GM, Coleman PJ, Kruszon-Moran D, Moyer LA, Lambert SB, Margolis HS. 1999. Prevalence of hepatitis B virus infection in the United States: The National Health and Nutrition Examination Surveys, 1976 through1994. Am J Public Health 89:14-18.
26. Meffre C, Le Strat Y, Delarocque-Astagneau E, Antona D, Desenclos JC. 2007. Prévalence des hépatites B et C en France en 2004. Saint-Maurice, mars: Institut de Veille Sanitaire p. 114. Available at: http://www.invs.sante.fr/publications/2006/prevalence-b-c/index.html.
27. Mohamed MK, Abdel-Hamid M, Mikhail NN, bdel-Aziz F, Medhat A, Magder LS, Fix AD, Strickland GT. 2005. Intrafamilial transmission of hepatitis C in Egypt. Hepatology 42:683-687.
28. Mohamed MK, Bakr I, El-Hoseiny M, Arafa N, Hassan A, Ismail S, Anwar M, Attala M, Rekacewicz C, Zalata K, Abdel-Hamid M, Esmat G, Fontanet A. 2006. HCV-related morbidity in a rural community of Egypt. Journal in Medical Virology 78:1185-1189.
29. Niederau C, Bemba G, Kautz A. 2006. Socioeconomic characteristics, quality of life, and state of knowledge of patients with hepatitis C viral infection in Germany - Socioeconomic aspects in hepatitis C. Z Gastroenterol 44:305-317.
30. Novelli LA, Sherman SG, Havens JR, Strathdee SA, Sapun M. 2005. Circumstances surrounding the first injection experience and their association with future syringe sharing behaviours in young urban injection drug users. Drug Alcohol Dependence 77:303-309.
31. Oberdorfer A, Wiggers JH, Bowman J, Lecathelinais C. 2003. Infection control practices among tattooists and body piercers in Sydney, Australia. Am J Infect Control 31:447-456.
32. Perez CM, Suarez E, Torres EA, Roman K, Colon V. 2005. Seroprevalence of hepatitis C virus and associated risk behaviours: A population-based study in San Juan, Puerto Rico. Int J Epidemiol 34:593-599.
33. Pillonel J, Le MN Girault A, David D, Laperche S. 2005. Epidemiological surveillance of blood donors and residual risk of blood-borne infections in France, 2001-2003. Transfus Clin Biol 12:239-246.
34. Rosenberg SD, Goodman LA, Osher FC, Swartz MS, Essock SM, Butterfield MI, Constantine NT, Wolford GL, Salyers MP. 2001. Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness. Am J Public Health 91:31-37.
35. Särndal CE, Swensson B, Wretman J, editors. 2003. Model assisted survey sampling. New York: Springer-Verlag.
36. Sen AR. 1953. On the estimate of the variance in sampling with varying probabilities. J Indian Soc Agric Statist 5:119-127.
37. Sheikh K, Mattingly S. 1981. Investigating non-response bias in mail surveys. J Epidemiol Community Health 35:293-296.
38. Shepard CW, Finelli L, Alter MJ. 2005. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5:558-567.
39. Sulkowski MS. 2008. Viral hepatitis and HIV coinfection. J Hepatol 48:353-367.
40. Sunter AB. 1977a. List sequential sampling with equal or unequal probabilities without replacement. Appl Statist 26:261-268.
41. Sunter AB. 1977b. Response burden, sample rotation and classification renewal in economic survey. Int Statist Rev 45:209-222.
42. Tickle M, Milsom KM, Blinkhorn AS, Worthington HV. 2003. Comparing different methods to detect and correct nonresponse bias in postal questionnaire studies. J Public Health Dent 63:112-118.
43. Tortu S, McMahon JM, Pouget ER, Hamid R. 2004. Sharing of noninjection drug-use implements as a risk factor for hepatitis C. Subst Use Misuse 39:211-224.
44. Tseng FC, O'Brien TR, Zhang M, Kral AH, Ortiz-Conde BA, Lorvick J, Busch MP, Edlin BR. 2007. Seroprevalence of hepatitis C virus and hepatitis B virus among San Francisco injection drug users, 1998-2000. Hepatology 46:666-671.
45. Van Damme P, Vellinga A. 1998. Epidemiology of hepatitis B and C in Europe. Acta Gastroenterol Belg 61:175-182.
46. van Loon AJ, Tijhuis M, Picavet HS, Surtees PG, Ormel J. 2003. Survey non-response in the Netherlands: Effects on prevalence estimates and associations. Ann Epidemiol 13:105-110.
47. World Health Organization. 1999. Hepatitis C - Global prevalence (update). Weekly Epidemiol Rec 74:425-427.
48. Yates F, Grundy PM. 1953. Selection without replacement from within strata with probability proportional to size. J R Statist Soc Ser B 15:253-261.